Lexaria
Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery
platforms, continues to progress the development and patenting of its
DehydraTECH(TM) platform. An article discussing the company reads, “The
DehydraTECH(TM) drug-delivery platform can be used to deliver substances in
edible or in beverage form, and in capsules, pills, syrups and more. Brands in
both Canada and the United States have licensed DehydraTECH to make their CBD
and cannabis beverages best-in-class. . . . Not only is ingestion a much safer
form of drug delivery, but DehydraTECH also delivers the active ingredient of
the substance at a rate that is up to five to ten times faster compared with
traditional edible products. A 2018 European clinical study demonstrated that
317% more CBD was delivered within half an hour when compared with a positive
control of equal strength (http://ibn.fm/pXIxY).
The substance being delivered is also rapidly absorbed, which means that people
can achieve the effect they are looking for more quickly than was previously
the case with edibles. For people looking for quick relief of pain, DehydraTECH
is a blessing.”
To view the full article, visit http://ibn.fm/KVdv3
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. is a global innovator in
drug-delivery platforms. Its patented DehydraTECH drug-delivery technology
changes the way active pharmaceutical ingredients enter the bloodstream,
promoting healthier ingestion methods, lower overall dosing and higher
effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption,
reduces time of onset and masks unwanted tastes for orally administered
bioactive molecules including cannabinoids, vitamins, non-steroidal
anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has
licensed DehydraTECH to multiple companies in the cannabis industry for use in
cannabinoid beverages, edibles and oral products, as well as to a world-leading
tobacco producer for the development of smokeless, oral-based nicotine
products. Lexaria operates a licensed, in-house research laboratory and holds a
robust intellectual property portfolio with 16 patents granted and over 60
patents pending worldwide. For more information, visit the company’s website
at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment